TEVA ANNOUNCES AZILECT NOW AVAILABLE IN THE U.K.

Teva Pharmaceutical and H. Lundbeck announced that Azilect, a once-daily treatment for Parkinson's disease (PD) both as monotherapy in patients with early PD and as an adjunct treatment in moderate to advanced disease, is now available in the U.K. This represents the first launch of Azilect in a member nation of the European Union following the issuance of a marketing authorisation by the European Commission earlier this year.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050627005455&newsLang=en)